Company profile KOD
After 34 days of this quarter the interest is at 14.0. Based on that we can calculate that during remaining 58 days it will total up to 38.0. Kodiak Sciences -stock -company expected interest is significantly lower compared to previous quarter (-64.2%) and same quarter last year (-71.4%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | - | 27 |
| 2019 | 117 333.3% QoQ | 62 -47.0% QoQ | 100 61.3% QoQ | 183 577.8% YoY 83.0% QoQ |
| 2020 | 107 -8.5% YoY -41.5% QoQ | 40 -35.5% YoY -62.6% QoQ | 84 -16.0% YoY 110.0% QoQ | 87 -52.5% YoY 3.6% QoQ |
| 2021 | 74 -30.8% YoY -14.9% QoQ | 69 72.5% YoY -6.8% QoQ | 106 26.2% YoY 53.6% QoQ | 109 25.3% YoY 2.8% QoQ |
| 2022 | 213 187.8% YoY 95.4% QoQ | 132 91.3% YoY -38.0% QoQ | 125 17.9% YoY -5.3% QoQ | 133 22.0% YoY 6.4% QoQ |
| 2023 | 143 -32.9% YoY 7.5% QoQ | 111 -15.9% YoY -22.4% QoQ | 106 -15.2% YoY -4.5% QoQ | 14 -89.5% YoY -86.8% QoQ |
The average 5 years interest of Kodiak Sciences -stock -company was 8.21 per week. The last year interest of Kodiak Sciences -stock -company compared to the last 5 years has changed by 2.07%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 35.38%.
There is not enough data for Kodiak Sciences treatments to provide analysis
There is not enough data for Kodiak Sciences treatments to provide correlation calculation
There is not enough data for Kodiak Sciences treatments to provide analysis
There is not enough data for tarcocimab tedromer to provide analysis
There is not enough data for tarcocimab tedromer to provide correlation calculation
There is not enough data for tarcocimab tedromer to provide analysis
There is not enough data for wet age-related macular degeneration treatment to provide analysis
There is not enough data for wet age-related macular degeneration treatment to provide correlation calculation
There is not enough data for wet age-related macular degeneration treatment to provide analysis
After 39 days of this quarter the interest is at 94.0. Based on that we can calculate that during remaining 52 days it will total up to 219.0. diabetic macular edema treatment expected interest is significantly higher compared to previous quarter (+271.2%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 56 | 0 -100.0% QoQ | 202 inf% QoQ | 279 38.1% QoQ |
| 2020 | 55 -1.8% YoY -80.3% QoQ | 203 inf% YoY 269.1% QoQ | 58 -71.3% YoY -71.4% QoQ | 137 -50.9% YoY 136.2% QoQ |
| 2021 | 57 3.6% YoY -58.4% QoQ | 50 -75.4% YoY -12.3% QoQ | 60 3.4% YoY 20.0% QoQ | 109 -20.4% YoY 81.7% QoQ |
| 2022 | 262 359.6% YoY 140.4% QoQ | 116 132.0% YoY -55.7% QoQ | 73 21.7% YoY -37.1% QoQ | 167 53.2% YoY 128.8% QoQ |
| 2023 | 250 -4.6% YoY 49.7% QoQ | 174 50.0% YoY -30.4% QoQ | 69 -5.5% YoY -60.3% QoQ | 59 -64.7% YoY -14.5% QoQ |
| 2024 | 94 -62.4% YoY 59.3% QoQ | - | - | - |
The average 5 years interest of diabetic macular edema treatment was 9.69 per week. The last year interest of diabetic macular edema treatment compared to the last 5 years has changed by 8.36%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by -4.72%.
After 38 days of this quarter the interest is at 40.0. Based on that we can calculate that during remaining 53 days it will total up to 96.0. retinal vein occlusion treatment expected interest is significantly lower compared to same quarter last year (-43.5%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 64 | 76 18.8% QoQ | 129 69.7% QoQ | 118 -8.5% QoQ |
| 2020 | 136 112.5% YoY 15.3% QoQ | 128 68.4% YoY -5.9% QoQ | 201 55.8% YoY 57.0% QoQ | 242 105.1% YoY 20.4% QoQ |
| 2021 | 79 -41.9% YoY -67.4% QoQ | 102 -20.3% YoY 29.1% QoQ | 104 -48.3% YoY 2.0% QoQ | 197 -18.6% YoY 89.4% QoQ |
| 2022 | 102 29.1% YoY -48.2% QoQ | 166 62.7% YoY 62.7% QoQ | 273 162.5% YoY 64.5% QoQ | 217 10.2% YoY -20.5% QoQ |
| 2023 | 170 66.7% YoY -21.7% QoQ | 31 -81.3% YoY -81.8% QoQ | 154 -43.6% YoY 396.8% QoQ | 122 -43.8% YoY -20.8% QoQ |
| 2024 | 40 -76.5% YoY -67.2% QoQ | - | - | - |
The average 5 years interest of retinal vein occlusion treatment was 10.97 per week. The last year interest of retinal vein occlusion treatment compared to the last 5 years has changed by -17.05%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by 12.62%.
There is not enough data for non-proliferative diabetic retinopathy treatment to provide analysis
There is not enough data for non-proliferative diabetic retinopathy treatment to provide correlation calculation
There is not enough data for non-proliferative diabetic retinopathy treatment to provide analysis
After 38 days of this quarter the interest is at 46.0. Based on that we can calculate that during remaining 53 days it will total up to 110.0. KSI-301 expected interest is significantly higher compared to same quarter last year (+54.9%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 79 | 268 239.2% QoQ | 84 -68.7% QoQ | 45 -46.4% QoQ |
| 2020 | 238 201.3% YoY 428.9% QoQ | 113 -57.8% YoY -52.5% QoQ | 120 42.9% YoY 6.2% QoQ | 125 177.8% YoY 4.2% QoQ |
| 2021 | 32 -86.6% YoY -74.4% QoQ | 180 59.3% YoY 462.5% QoQ | 282 135.0% YoY 56.7% QoQ | 181 44.8% YoY -35.8% QoQ |
| 2022 | 132 312.5% YoY -27.1% QoQ | 286 58.9% YoY 116.7% QoQ | 0 -100.0% YoY -100.0% QoQ | 116 -35.9% YoY inf% QoQ |
| 2023 | 71 -46.2% YoY -38.8% QoQ | 68 -76.2% YoY -4.2% QoQ | 61 inf% YoY -10.3% QoQ | 164 41.4% YoY 168.9% QoQ |
| 2024 | 46 -35.2% YoY -72.0% QoQ | - | - | - |
The average 5 years interest of KSI-301 was 10.35 per week. The last year interest of KSI-301 compared to the last 5 years has changed by -37.0%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -35.32%.
There is not enough data for KSI-501 to provide analysis
There is not enough data for KSI-501 to provide correlation calculation
There is not enough data for KSI-501 to provide analysis
There is not enough data for KSI-601 to provide analysis
There is not enough data for KSI-601 to provide correlation calculation
There is not enough data for KSI-601 to provide analysis